COMMUNIQUÉS West-GlobeNewswire

First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton
09/09/2025
Medicare Advantage claim processed in less than thirty days Additional progress with traditional Medicare claim approvals has accelerated timelines to payment in 2025 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. [...]
Counterpart Health Launches Integrated Scribing, Supercharging Counterpart Assistant with Smarter, Seamless Scribing Built for Value-Based Care
09/09/2025
The latest AI-powered feature in Counterpart Assistant streamlines documentation, enhances physician workflows, and raises the bar for value-based care across practice settings at no additional cost to users SAN [...]
Aphaia Pharma Initiates Second Phase 2 Trial of Oral Candidate in Obesity
09/09/2025
Second Phase 2 trial builds on encouraging initial results from a prior Phase 2 study Aphaia’s formulation activates gastrointestinal nutrient-sensing signaling pathways to modify the course of obesity and associated [...]
Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome
09/09/2025
New Episode Highlights the Social and Emotional Impact of Netherton Syndrome, the Importance of Supportive Communities, and the Urgent Need for an Approved Treatment ASHBURN, Va., Sept. 09, 2025 (GLOBE NEWSWIRE) -- [...]
Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million
09/09/2025
- Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to provide update at the H.C. Wainwright 27th Annual [...]
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
09/09/2025
BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
09/09/2025
European expansion in September across Georgia, Italy, Lithuania, Poland, Romania, Spain, and US 13 subjects recruited (treated, enrolled, or screened) Forecasts total recruitment of 20 or more subjects by end of [...]
Parexel Establishes New Global Headquarters in Raleigh’s North Hills Innovation District
09/09/2025
Company relocation within the Raleigh-Durham area underscores commitment to sustainability, workplace innovation and strong presence in North Carolina RALEIGH, N.C., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading [...]
Aviv Clinics Showcases New Study on Hyperbaric Oxygen Therapy’s Effectiveness in Improving Post-Concussion Symptoms from Childhood Traumatic Brain Injury
09/09/2025
Study demonstrates how hyperbaric oxygen therapy can improve cognitive function in adults with long-term effects of childhood brain injury, offering new hope for post-concussion syndrome patients ORLANDO, Fla., Sept. 09 [...]
All Heart Homecare Expands Services with Specialized Holocaust Program
09/09/2025
BROOKLYN, N.Y., Sept. 09, 2025 (GLOBE NEWSWIRE) -- All Heart Homecare — Brooklyn’s premier home care agency and a trusted partner for families across New York City for over 13 years — is proud to expand its wide range [...]
Scenic Biotech Appoints Dr. Roland W. Bürli as CSO to Advance Pipeline of Modifier Therapies in Neuro- and Metabolic Diseases
09/09/2025
Scenic Biotech taps Dr. Bürli as Chief Scientific Officer to lead development of innovative drug candidate pipeline fueled by the company’s Cell-Seq platform. Amsterdam, the Netherlands, September 09, 2025 – Scenic [...]
RYBREVANT®▼ (amivantamab) en association avec LAZCLUZE®▼ (lazertinib) réduit la résistance acquise à l’osimertinib dans le traitement de première intention du cancer du poumon non à petites cellules avancé avec mutations de l’EGFR
09/09/2025
De nouvelles données démontrent que l’association avec l’amivantamab réduit significativement les mutations courantes de résistance à l’EGFR et au MET observées avec les ITK de l’EGFR 1 BEERSE, BELGIQUE, Sept. 09, 2025 [...]
Biosplice Therapeutics Announces First Patient Dosed in NCI-Sponsored Clinical Trial of Cirtuvivint in Acute Myeloid Leukemia and Myelodysplastic Syndromes
09/09/2025
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual- [...]
Persephone Biosciences Unveils First-Of-Its-Kind Synbiotic Designed To Restore Critical Gut Microbes In Babies
09/09/2025
Newly released data shows that nine in ten babies lack critical gut microbes needed for healthy development. Persephone’s Daily Synergistic Synbiotic, built on the largest and most comprehensive U.S. infant gut [...]
CHAPPER healthcare, AscellaHealth’s Global Pharmaceutical Distributor, Assumes Presidency of EUROPACCESS, Enhancing Access to Innovative Medicines
09/09/2025
WATFORD, United Kingdom and BERWYN, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- CHAPPER healthcare , AscellaHealth’s global pharmaceutical wholesaler, distributor and commercialization service provider, announces its [...]
Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis
09/09/2025
THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an [...]
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
09/09/2025
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease Pacibekitug is a promising targeted therapy with [...]
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
09/09/2025
– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, [...]
Valley Wellness to open luxury behavioral health facility in Corona, CA
09/09/2025
CORONA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Valley Wellness , a California-based behavioral health treatment company, has announced the opening of its first facility in Corona, CA. The company has selected a 4.2- [...]

Pages